Vandenplas Yvan, Alarcon Pedro, Fleischer David, Hernell Olle, Kolacek Sanja, Laignelet Hugo, Lönnerdal Bo, Raman Rita, Rigo Jacques, Salvatore Silvia, Shamir Raanan, Staiano Annamaria, Szajewska Hania, Van Goudoever Hans J, von Berg Andrea, Lee Way S
*Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium †National Institute of Child Health, Lima, Perú ‡Denver School of Medicine and Children's Hospital Colorado, University of Colorado §Pediatrics, Department of Clinical Sciences, Umeå University, Sweden ||Department of Pediatrics, Children's Hospital, University of Zagreb Medical School, Zagreb, Croatia ¶Centro de Gastroenterologia y Endoscopia pediatricas Gastroped & Dermatosoluciones Ltda', Bogota, Colombia #Department of Nutrition, University of California, Davis **Department of Pediatrics, University of Oklahoma Health Sciences Center and Children's Hospital, Oklahoma City ††Department of Neonatology, University of Liège CHR Citadelle, Liege, Belgium ‡‡Paediatric Department, University of Insubria, Varese, Italy §§Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel-Aviv University, Israel ||||Department of Translational Medical Science, Section of Paediatrics, University of Naples Federico II, Naples, Italy ¶¶Department of Paediatrics, The Medical University of Warsaw, Poland ##Department of Pediatrics, Emma Children's Hospital-AMC and VU University Medical Center, Amsterdam, The Netherlands ***Research Institute, Department of Pediatrics, Marien-Hospital-Wesel, Wesel, Germany †††Department of Paediatrics, Faculty of Medicine, University of Malaysia, Kuala Lumpur, Malaysia.
J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):22-35. doi: 10.1097/MPG.0000000000001014.
Partially hydrolyzed formulas (pHFs) are increasingly used worldwide, both in the prevention of atopic disease in at-risk infants and in the therapeutic management of infants with functional gastrointestinal manifestations. Because prevention is always preferable to treatment, we reviewed the literature aiming to find an answer for the question whether pHF may be recommended for feeding all infants if breast-feeding is not possible. PubMed and Cochrane databases were searched up to December 2014. In addition, to search for data that remained undetected by the searches, we approached authors of relevant articles and major producers of pHFs asking for unpublished data. Because few data were found, nonrandomized, controlled trials and trials in preterm infants were included as well. Overall, only limited data could be found on the efficacy and safety of pHF in healthy term infants. Available data do not indicate that pHFs are potentially harmful for healthy, term infants. With respect to long-term outcomes, particularly referring to immune, metabolic and hormonal effects, data are, however, nonexistent. From a regulatory point of view, pHFs meet the nutrient requirements to be considered as standard formula for term healthy infants. Cost, which is different from country to country, should be considered in the decision-making process. Based on limited available data, the use of pHF in healthy infants is safe with regard to growth. The lack of data, in particular for metabolic consequences and long-term outcomes, is, however, the basis for our recommendation that health authorities should develop and support long-term follow-up studies. Efficacy and long-term safety data are required before a recommendation of this type of formula for all infants can be made.
部分水解配方奶粉（pHF）在全球范围内的使用越来越广泛，既用于预防高危婴儿的过敏性疾病，也用于治疗有功能性胃肠道表现的婴儿。由于预防总是优于治疗，我们查阅了文献，旨在寻找一个问题的答案，即如果无法进行母乳喂养，pHF是否可推荐用于喂养所有婴儿。检索了截至2014年12月的PubMed和Cochrane数据库。此外，为了查找检索未发现的数据，我们联系了相关文章的作者和pHF的主要生产商，索要未发表的数据。由于找到的数据很少，非随机对照试验和早产儿试验也被纳入。总体而言，关于pHF在健康足月儿中的疗效和安全性，仅能找到有限的数据。现有数据并未表明pHF对健康足月儿有潜在危害。然而，关于长期结局，特别是免疫、代谢和激素方面的影响，尚无数据。从监管角度来看，pHF满足作为足月儿健康婴儿标准配方奶粉的营养要求。在决策过程中应考虑不同国家不同的成本。基于有限的现有数据，pHF在健康婴儿中的使用对生长是安全的。然而，缺乏数据，特别是关于代谢后果和长期结局的数据，是我们建议卫生当局应开展并支持长期随访研究的依据。在能够推荐这类配方奶粉用于所有婴儿之前，需要疗效和长期安全性数据。
